Arbutus Biopharma Corp Retained Earnings
Arbutus Biopharma Corp (ABUS) had Retained Earnings of -$1.22 billion as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-12
- 2013-12-31: Retained Earnings (Accumulated Deficit) -167.03M CAD.
- 2012-12-31: Retained Earnings (Accumulated Deficit) -152.96M CAD; Retained Earnings (Accumulated Deficit) as first filed -229.05M CAD.
- 2011-12-31: Retained Earnings (Accumulated Deficit) -258.85M CAD.
- 2010-12-31: Retained Earnings (Accumulated Deficit) -248.91M CAD.
CAD
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2013-12-31 | -167.03M CAD 10-K · filed 2014-03-28 | |
| 2012-12-31 | -152.96M CAD 10-K · filed 2014-03-28 | -229.05M CAD 20-F · filed 2013-03-27 |
| 2011-12-31 | -258.85M CAD 20-F · filed 2013-03-27 | |
| 2010-12-31 | -248.91M CAD 20-F · filed 2012-03-27 |
USD
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | -$1.22B 10-Q · filed 2026-08-12 | |
| 2026-03-31 | -$1.21B 10-Q · filed 2026-05-13 | |
| 2025-12-31 | -$1.38B 10-Q · filed 2026-08-12 | |
| 2025-09-30 | -$1.38B 10-Q · filed 2025-11-13 | |
| 2025-06-30 | -$1.37B 10-Q · filed 2025-08-06 | |
| 2025-03-31 | -$1.37B 10-Q · filed 2025-05-14 | |
| 2024-12-31 | -$1.35B 10-K · filed 2026-03-23 | |
| 2024-09-30 | -$1.33B 10-Q · filed 2024-11-06 | |
| 2024-06-30 | -$1.31B 10-Q · filed 2024-08-08 | |
| 2024-03-31 | -$1.29B 10-Q · filed 2024-05-02 | |
| 2023-12-31 | -$1.28B 10-K · filed 2025-03-27 | |
| 2023-09-30 | -$1.26B 10-Q · filed 2023-11-07 | |
| 2023-06-30 | -$1.24B 10-Q · filed 2023-08-03 | |
| 2023-03-31 | -$1.22B 10-Q · filed 2023-05-04 | |
| 2022-12-31 | -$1.20B 10-K · filed 2024-03-05 | |
| 2022-09-30 | -$1.18B 10-Q · filed 2022-11-09 | |
| 2022-06-30 | -$1.16B 10-Q · filed 2022-08-04 | |
| 2022-03-31 | -$1.15B 10-Q · filed 2022-05-05 | |
| 2021-12-31 | -$1.13B 10-K · filed 2023-03-02 | |
| 2021-09-30 | -$1.11B 10-Q · filed 2021-11-04 | |
| 2021-06-30 | -$1.09B 10-Q · filed 2021-08-05 | |
| 2021-03-31 | -$1.07B 10-Q · filed 2021-05-05 | |
| 2020-12-31 | -$1.05B 10-K · filed 2022-03-03 | |
| 2020-09-30 | -$1.03B 10-Q · filed 2020-11-05 | |
| 2020-06-30 | -$1.00B 10-Q · filed 2020-08-07 | |
| 2020-03-31 | -$986.93M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | -$970.09M 10-K · filed 2021-03-04 | |
| 2019-09-30 | -$942.56M 10-Q · filed 2019-11-06 | |
| 2019-06-30 | -$857.26M 10-Q · filed 2019-08-05 | |
| 2019-03-31 | -$831.19M 10-Q · filed 2019-05-06 | |
| 2018-12-31 | -$805.22M 10-K · filed 2020-03-05 | |
| 2018-09-30 | -$784.33M 10-Q · filed 2018-11-07 | |
| 2018-06-30 | -$757.28M 10-Q · filed 2018-08-03 | |
| 2018-03-31 | -$757.84M 10-Q · filed 2018-05-04 | |
| 2017-12-31 | -$738.07M 10-K · filed 2019-03-07 | |
| 2017-09-30 | -$699.63M 10-Q · filed 2017-11-02 | |
| 2017-06-30 | -$688.03M 10-Q · filed 2017-08-03 | |
| 2017-03-31 | -$669.78M 10-Q · filed 2017-05-04 | |
| 2016-12-31 | -$652.75M 10-K · filed 2018-03-16 | -$651.15M 10-K · filed 2017-03-22 |
| 2016-09-30 | -$432.45M 10-Q · filed 2016-11-03 | |
| 2016-06-30 | -$412.86M 10-Q · filed 2016-08-04 | |
| 2016-03-31 | -$282.86M 10-Q · filed 2016-05-04 | |
| 2015-12-31 | -$266.99M 10-K · filed 2017-03-22 | |
| 2015-09-30 | -$261.72M 10-Q · filed 2015-11-05 | |
| 2015-06-30 | -$232.74M 10-Q · filed 2015-08-07 | |
| 2015-03-31 | -$217.85M 10-Q · filed 2015-05-06 | |
| 2014-12-31 | -$205.86M 10-K · filed 2016-03-09 | |
| 2014-09-30 | -$199.70M 10-Q · filed 2014-11-07 | |
| 2014-06-30 | -$191.09M 10-Q · filed 2014-08-14 | |
| 2014-03-31 | -$185.01M 10-Q · filed 2014-05-14 | |
| 2013-12-31 | -$167.03M 10-K · filed 2015-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |